Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

Area of Science:

• Oncology
• Medical Science
• Pharmacology

Background:

• Well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are distinct subtypes often driven by CDK4 amplification.
• CDK4/6 inhibitors like palbociclib show therapeutic promise, but real-world data for liposarcoma treatment is limited.

Purpose of the Study:

• To evaluate the real-world effectiveness and safety of palbociclib monotherapy in patients with advanced WDLPS or DDLPS.
• To assess progression-free survival (PFS), overall survival (OS), response rates, and adverse events associated with palbociclib treatment.

Main Methods:

• Retrospective analysis of 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy.
• Data collected from 16 Turkish Oncology Group centers between 2019 and 2022.
• Outcomes assessed included PFS, OS, objective response rate (ORR), disease control rate (DCR), and safety profile.

Main Results:

• Median PFS was 5.3 months and median OS was 9.1 months.
• No objective responses were observed (ORR 0%), but disease control was achieved in 57.1% of patients.
• Common adverse events included anemia (52.4%) and neutropenia (33.3%); 71.4% experienced some adverse events.

Conclusions:

• Palbociclib monotherapy exhibited modest activity, with disease stabilization observed in a subset of patients with advanced liposarcoma.
• The findings underscore the need for biomarker-driven approaches and combination strategies to enhance therapeutic efficacy in WDLPS and DDLPS.